Please use this identifier to cite or link to this item:
Title: The arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target
Authors: Ng K.P. 
Manjeri A. 
Lee L.M. 
Chan Z.E. 
Tan C.Y.
Tan Q.D. 
Majeed A. 
Lee K.L. 
Chuah C. 
Suda T. 
Ong S.T. 
Issue Date: 2018
Publisher: Public Library of Science
Citation: Ng K.P., Manjeri A., Lee L.M., Chan Z.E., Tan C.Y., Tan Q.D., Majeed A., Lee K.L., Chuah C., Suda T., Ong S.T. (2018). The arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS ONE 13 (10) : e0205254. ScholarBank@NUS Repository.
Abstract: Cancer cells, including in chronic myeloid leukemia (CML), depend on the hypoxic response to persist in hosts and evade therapy. Accordingly, there is significant interest in drugging cancerspecific hypoxic responses. However, a major challenge in leukemia is identifying differential and druggable hypoxic responses between leukemic and normal cells. Previously, we found that arginase 2 (ARG2), an enzyme of the urea cycle, is overexpressed in CML but not normal progenitors. ARG2 is a target of the hypoxia inducible factors (HIF1-a and HIF2-?), and is required for the generation of polyamines which are required for cell growth. We therefore explored if the clinically-tested arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) would be effective against leukemic cells under hypoxic conditions. Remarkably, nor-NOHA effectively induced apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Co-treatment with nor-NOHA overcame hypoxia-mediated resistance towards BCR-ABL1 kinase inhibitors. While nor-NOHA itself is promising in targeting the leukemia hypoxic response, we unexpectedly found that its anti-leukemic activity was independent of ARG2 inhibition. Genetic ablation of ARG2 using CRISPR/Cas9 had no effect on the viability of leukemic cells and their sensitivity towards nor-NOHA. This discrepancy was further evidenced by the distinct effects of ARG2 knockouts and nor-NOHA on cellular respiration. In conclusion, we show that nor - NOHA has significant but off-target anti-leukemic activity among ARG2-expressing hypoxic cells. Since nor-NOHA has been employed in clinical trials, and is widely used in studies on endothelial dysfunction, immunosuppression and metabolism, the diverse biological effects of nor-NOHA must be cautiously evaluated before attributing its activity to ARG inhibition. 7copy; 2018 Ng et al. � 2018 Public Library of Science. All rights reserved.
Source Title: PLoS ONE
ISSN: 19326203
DOI: 10.1371/journal.pone.0205254
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
journal.pone.0205254.pdf5.41 MBAdobe PDF




checked on Jun 4, 2020

Page view(s)

checked on Jun 4, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.